CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat™ Kit. The kit provides two products within one package: HylatopicPlus™ Emollient Foam indicated to manage and relieve burning, itching and pain that can accompany skin dermatoses such as atopic dermatitis (eczema) and Aurstat™ Skin & Wound HydroGel, which is used to relieve skin irritation, minor abrasions and lacerations — and also can be used on intact skin.
"We believe that the newly launched HylatopicPlus-Aurstat™ Kit provides physicians and patients greater convenience when skin barrier dysfunction and S. aureus colonization are present in the same patient," said Doug Abel, General Manager of Onset Dermatologics. "The kit provides two therapies in one prescription for a single co-pay, which may improve patient adherence to physician instructions and thus, result in improved clinical outcomes."
HylatopicPlus™ Emollient Foam is formulated to rapidly hydrate the stratum corneum (the top layer of the epidermis) and provide a semi-permeable barrier that protects against irritants and excessive water loss through the skin. HylatopicPlus™ incorporates hyaluronic acid to deliver a blend of physiologic lipids, including ceramide, to restore healthy barrier function. HylatopicPlus™ has been clinically proven to improve the symptoms of atopic dermatitis.
Aurstat™ HydroGel is intended for over-the-counter use on minor skin abrasions and lacerations — and for use on intact skin. Aurstat™ contains a unique shelf-stable formulation of hypochlorous acid in hydrogel form. In a laboratory setting, Aurstat™ killed 99.99% of Staphylococcus aureus (S. aureus) within 30 seconds post-application. Aurstat™ HydroGel is non-irritating and can be safely used around the eyes, nose and mouth.
The HylatopicPlus-Aurstat™ Kit is now available in the U.S. by prescription only.
Important Safety Information for HylatopicPlus™ Emollient Foam
HylatopicPlus™ is contraindicated in persons with a known hypersensitivity to any of the components of the formulation. If clinical signs of infection are present, appropriate treatment should be initiated; use of HylatopicPlus™ Emollient Foam may be continued
during the anti-infective therapy.
About Onset Dermatologics
Onset Dermatologics (www.onsetdermatologics.com) is dedicated to providing new, optimized, innovative, practical and cost-effective pharmaceutical products to the healthcare market in an effort to improve the quality of life for patients. The company markets 11 products based on its proprietary Delevo® foam technology platform that is designed to deliver enhanced penetration of proven active ingredients while improving patient compliance.
About PreCision Dermatology, Inc.
Headquartered in Cumberland RI, PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology will expand quickly through acquisitions, in-licensing, co-marketing opportunities as well as internally generated therapies.
SOURCE Onset Dermatologics